1. , , , et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000;31:1062–1068.
2. , , , et al. Vascular cognitive impairment. Lancet Neurol 2003;2:89–98.
3. , Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009;8:1006–1018.
4. , , , et al. Long-term prognosis of Chinese patients with a lacunar infarct associated with small vessel disease: a five-year longitudinal study. Int J Stroke 2009;4:81–88.
5. , , Race–ethnic differences in stroke risk factors among hospitalized patients with cerebral infarction: the Northern Manhattan Stroke Study. Neurology 1995;45:659–663.
6. , , , et al. Factors affecting one year mortality and functional outcome after first ever ischemic stroke in the region of Antalya, Turkey (a hospital-based study). Acta Neurol Belg 2004;104:154–160.
7. , , , et al. Stroke recurrence within the first year following cerebral infarction – Tottori University Lacunar Infarction Prognosis Study (TULIPS). Acta Neurol Scand 2004;110:343–349.
8. , , , , Survey of the causes of stroke among Mexican Americans in South Texas. Tex Med 1998;94:62–67.
9. , , , Long-term prognosis, by stroke subtypes, after a first-ever stroke: a hospital-based study over a 20-year period. Cerebrovasc Dis 2004;18:111–116.
10. Lacunar strokes and infarcts: a review. Neurology 1982;32:871–876.
11. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002;12:358–370.
12. , , , Tertiary microvascular territories define lacunar infarcts in the basal ganglia. Ann Neurol 2005;58:18–30.
13. Lacunes: small, deep cerebral infarcts. Neurology 1965;15:774–784.
14. The arterial lesions underlying lacunes. Acta Neuropathol 1968;12:1–15.
15. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689–701.
16. , , , et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011;6:164–175.
17. , , , , Long-term prognosis of symptomatic lacunar infarcts. A hospital-based study. Stroke 1994;25:2005–2009.
18. , , , Stroke rates in patients with lacunar and large vessel cerebral infarctions. J Neurol Sci 1993;114:128–137.
19. , , , et al. Long-term prognosis of patients with lacunar syndromes. Acta Neurol Scand 1986;74:224–229.
20. , , , et al. Stroke recurrence within two years after ischemic infarction. Stroke 1991;22:155–161.
21. , , , Leukoaraiosis in relation to prognosis for patients with lacunar infarction. Stroke 1992;23:1434–1438.
22. , , , Lacunar versus non-lacunar infarcts: pathogenetic and prognostic differences. J Neurol Neurosurg Psych 1992;55:441–445.
23. , , , Stroke subtype is an age-independent predictor of first-year survival. Neuroepidemiology 1992;11:190–195.
24. , Prognosis for survival, handicap and recurrence of stroke in lacunar and superficial infarction. Cerebrovasc Dis 1993;3:221–226.
25. , , Presumed pathogenetic mechanisms of recurrent stroke after lacunar infarction. Cerebrovasc Dis 1996;6:128–136.
26. , , Long-term prognosis of first-ever lacunar strokes. A hospital-based study. Stroke 1996;27:661–666.
27. , , , , Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. Stroke 1998;29:570–576.
28. , , Pure motor stroke from presumed lacunar infarct: long-term prognosis for survival and risk of recurrent stroke. Stroke 2001;32:2592–2596.
29. , Survival and recurrent strokes in patients with different subtypes of stroke: a 14-year follow-up study. Cerebrovasc Dis 2001;12:171–180.
30. , , , et al. Lacunar stroke: transoesophageal echocardiographic factors influencing long-term prognosis. Cerebrovasc Dis 2001;12:325–330.
31. , , , et al. Twenty-four-hour blood pressure and MRI as predictive factors for different outcomes in patients with lacunar infarct. Stroke 2002;33:297–305.
32. , , , Stroke subtype and mortality. A follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 2003;56:262–268.
33. , , , et al. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy: a prospective, hospital-based study. Stroke 2009;40:3679–3684.
34. , , , et al. Relationship between three-year survival and functional outcome at discharge from acute-care hospitals in each subtype of first-ever ischemic stroke patients. Intern Med 2011;50:1377–1383.
35. , , , et al. Cardioembolic but not other stroke subtypes predict mortality independent of stroke severity at presentation. Stroke Res Treat 2011;2011:281496.
36. , , , Ischemic stroke related to intracranial branch atheromatous disease and comparison with large and small artery diseases. J Neurological Sci 2011;303:80–84.
37. , Temporal distribution and magnitude of the vulnerability period around stroke depend on stroke subtype. Cerebrovasc Dis 2011;32:246–253.
38. , , , et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology 2011;76:734–739.
39. , , , The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
40. , , , , Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991;22:1236–1241.
41. , , , Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626–634.
42. , , , Predicting survival for one year among different subtypes of stroke. Results from the Perth Community Stroke Study. Stroke 1994;25:1935–1944.
43. , , , , Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke 2001;32:2735–2740.
44. , , , et al. Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psych 2005;76:368–372.
45. , , , et al. Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population-based study. Stroke 2008;39:1945–1951.
46. , , , et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New Engl J Med 2001;345:1444–1451.
47. , , , et al. Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death: subgroup analyses from the Warfarin–Aspirin Recurrent Stroke study. Cerebrovasc Dis 2006;22:4–12.
48. , , , et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–337.
49. , , , et al. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006;355:549–559.
50. , , , et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. New Engl J Med 2008;359:1238–1251.
51. , , , et al. Cilostazol for Prevention of Secondary Stroke (CSPS2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010;9:959–968.
52. , , , et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. New Engl J Med 2012;367:817–825.
53. Long-term prognosis after lacunar infarction. Lancet Neurol 2003;2:238–245.
54. , Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005;128(Pt 11):2507–2517.
55. Lacunar infarcts: no black holes in the brain are benign. Pract Neurol 2008;8:222–228.
56. , , , et al. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol 2012;72:351–362.
57. , , , et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870–947.
58. . Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995;333:1581–1587.
59. , , , , Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology 2003;61:71–75.
60. , , , et al. Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol 2006;55:70–73.
61. , , , et al. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol 2010;17:1054–1060.
62. , , , et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke 2011;42:102–106.
63. , , , et al. Clinical and radiological features of stroke patients with poor outcomes who do not receive intravenous thrombolysis because of mild symptoms. Eur Neurol 2012;69:4–7.
64. , , , et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines–Stroke. Stroke 2011;42:3110–3115.
65. , , , et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37:2463–2466.
66. , , , , Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology 2007;68:1020–1024.
67. , , , et al. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA stroke study. Cerebrovasc Dis 2008;26:120–125.
68. , , , Postthrombolysis intracranial hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review and meta-analysis. Int J Stroke 2013;8:348–356.
69. , , Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging 2004;14:54–57.
70. , , , et al. Progressive lacunar stroke: review of mechanisms, prognostic features, and putative treatments. Int J Stroke 2012;7:321–329.
71. , , , , The stroke syndrome of striatocapsular infarction. Brain 1991;114(Pt 1A):51–70.
72. , , , , The capsular warning syndrome: pathogenesis and clinical features. Neurology 1993;43:957–962.
73. , , , Population-based study of capsular warning syndrome and prognosis after early recurrent TIA. Neurology 2012;79:1356–1362.
74. , , , et al. Fast Assessment of Stroke and Transient ischaemic attack to prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961–969.
75. , , , et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. New Engl J Med 2013;369:11–19.
76. , , , Risk factors and outcome of patients with symptomatic intracranial stenosis presenting with lacunar stroke. Stroke 2012;43:1230–1233.
77. , , , Pathology of lacunar ischemic stroke in humans – a systematic review. Brain Pathol 2012;22:583–591.
78. , , , et al. “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983;14:5–14.
79. , , , et al. The Canadian–American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215–1220.
80. . CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
81. , , , et al. Cilostazol Stroke Prevention Study: a placebo-controlled doubleblind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000;9:147–157.
82. , , , et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003;289:2947–2957.
83. , , , , Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–1673.
84. , , , et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011;377:2013–2022.
85. , , , et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the Cilostazol Stroke Prevention Study. Cerebrovasc Dis 2008;26:63–70.
86. , , , et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461–2469.
87. , , , et al. Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998;19:1538–1546.
88. , , , et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345:494–502.
89. , , , et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227–276.
90. , , , et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean National Health System Prospective Cohort Study. BMJ 2006;333:22.
91. , , , , Serum cholesterol levels and six-year mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. New Engl J Med 1989;320:904–910.
92. , , , et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
93. , Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453–463.
94. , , , et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009;40:1405–1409.
95. , , , et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70(24 Pt 2):2364–2370.
96. , , , et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 2010;376:112–123.
97. , , , Blood pressure and coronary heart disease. Lancet 1990;336:370–371.
98. , , , et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827–838.
99. , , , et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765–774.
100. . PROGRESS – The Perindopril Protection aGainst Recurrent Stroke Study: characteristics of the study population at baseline. J Hypertens 1999;17:1647–1655.
101. , , , et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997;28:2557–2562.
102. , , Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741–2748.
103. , , , et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013;382:507–515.
104. , , , et al. Differing risk factor profiles of ischemic stroke subtypes: evidence for a distinct lacunar arteriopathy? Stroke 2010;41:624–629.
105. , , , et al. Need for extensive diagnostic work-up for patients with lacunar stroke. J Neurol 2008;255:637–642.
106. , , , . Comparison of the CHADS2, CHADS2–VASc and HAS–BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Thromb Haemostasis 2013;110:1074–1079.
107. , , Is investigating for carotid artery disease warranted in non-cortical lacunar infarction? Stroke 2011;42:217–220.
108. , , , , Severe ipsilateral carotid stenosis and middle cerebral artery disease in lacunar ischaemic stroke: innocent bystanders? J Neurol 2002;249:266–271.
109. , , , , . Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. North American Symptomatic Carotid Endarterectomy Trial Group. Neurology 2000;54:660–666.
110. , , The appropriate use of carotid endarterectomy. CMAJ 2002;166:1169–1179.